Abstract

The present investigation is aimed at improving the ocular bioavailability of a poorly water soluble drug, celecoxib, to offer new options in the treatment of chronic eye diseases, such as age-related macular degeneration and diabetic retinopathy. To do so, we developed a novel formulation of drug-loaded poly(ortho ester) nanoparticles (NPs). We characterized the NPs in terms of size, morphology, controlled-release, degradation and cytocompatibity. Stable and transparent NP emulsions were prepared following a double emulsion solvent diffusion method employing poloxamer 188 as a stabilizer. Physical properties showed a narrow range size distribution of 151–164nm with spherical morphology, negative zeta potentials and remarkably high celecoxib encapsulation efficiency (98%) and loading (64%) of poly(ortho ester) NPs. Drug release followed a zero-order release by a surface erosion-controlled mechanism without any burst effect. Degradation of poly(ortho ester) NPs was observed by measuring the concentration of initial degradation product such as, lactic acid. MTT studies revealed minimal toxicity of NPs (up to 1mg/ml) toward HEK 293 cells. Poly(ortho ester) NPs were not internalized by either Müller or HEK 293 cells, which is highly desirable for a drug carrier to deliver the drugs for prolonged periods to the back of eye. These features have the potential to decrease the number of intraocular injections required to treat chronic eye diseases.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.